Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Genetic profiling of myeloproliferative disorders by single-nucleotide polymorphism oligonucleotide microarray.

Kawamata N, Ogawa S, Yamamoto G, Lehmann S, Levine RL, Pikman Y, Nannya Y, Sanada M, Miller CW, Gilliland DG, Koeffler HP.

Exp Hematol. 2008 Nov;36(11):1471-9. doi: 10.1016/j.exphem.2008.06.006. Epub 2008 Aug 23.

2.

JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.

Kilpivaara O, Levine RL.

Leukemia. 2008 Oct;22(10):1813-7. doi: 10.1038/leu.2008.229. Epub 2008 Aug 28. Review.

PMID:
18754026
3.

Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm.

Rumi E, Harutyunyan A, Elena C, Pietra D, Klampfl T, Bagienski K, Berg T, Casetti I, Pascutto C, Passamonti F, Kralovics R, Cazzola M.

Am J Hematol. 2011 Dec;86(12):974-9. doi: 10.1002/ajh.22166. Epub 2011 Sep 22.

5.

[Myeloproliferative diseases caused by JAK2 mutation].

Nagata K, Shimoda K.

Rinsho Byori. 2009 Apr;57(4):357-64. Review. Japanese.

PMID:
19489438
6.

Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms.

Milosevic Feenstra JD, Nivarthi H, Gisslinger H, Leroy E, Rumi E, Chachoua I, Bagienski K, Kubesova B, Pietra D, Gisslinger B, Milanesi C, Jäger R, Chen D, Berg T, Schalling M, Schuster M, Bock C, Constantinescu SN, Cazzola M, Kralovics R.

Blood. 2016 Jan 21;127(3):325-32. doi: 10.1182/blood-2015-07-661835. Epub 2015 Sep 30.

7.

MPL W515L mutation in Chinese patients with myeloproliferative diseases.

Xu W, Li JY, Xia J, Zhang SJ, Fan L, Qiao C.

Leuk Lymphoma. 2008 May;49(5):955-8. doi: 10.1080/10428190802035966.

PMID:
18464114
8.

Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens.

Moliterno AR, Williams DM, Rogers O, Isaacs MA, Spivak JL.

Exp Hematol. 2008 Nov;36(11):1480-6. doi: 10.1016/j.exphem.2008.05.006. Epub 2008 Aug 23.

9.

Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.

Duangnapasatit B, Rattarittamrong E, Rattanathammethee T, Hantrakool S, Chai-Adisaksopha C, Tantiworawit A, Norasetthada L.

Asian Pac J Cancer Prev. 2015;16(12):5013-8.

10.

The analysis of JAK2 and MPL mutations and JAK2 single nucleotide polymorphisms in MPN patients by MassARRAY assay.

Zhang SJ, Qiu HX, Li JY, Shi JY, Xu W.

Int J Lab Hematol. 2010 Aug 1;32(4):381-6. doi: 10.1111/j.1751-553X.2009.01208.x. Epub 2010 Mar 23.

PMID:
20331763
11.

Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.

Michiels JJ, Berneman Z, Schroyens W, De Raeve H.

Acta Haematol. 2015;133(1):36-51. doi: 10.1159/000358580. Epub 2014 Aug 7. Review.

PMID:
25116092
12.

JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.

Hussein K, Bock O, Theophile K, von Neuhoff N, Buhr T, Schlué J, Büsche G, Kreipe H.

Exp Hematol. 2009 Oct;37(10):1186-1193.e7. doi: 10.1016/j.exphem.2009.07.005. Epub 2009 Jul 17.

PMID:
19616600
13.

Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?

Ahmed RZ, Rashid M, Ahmed N, Nadeem M, Shamsi TS.

Asian Pac J Cancer Prev. 2016;17(3):923-6. Review.

14.

Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis.

Williams DM, Kim AH, Rogers O, Spivak JL, Moliterno AR.

Exp Hematol. 2007 Nov;35(11):1641-6. Epub 2007 Oct 17.

15.

Molecular and genetic bases of myeloproliferative disorders: questions and perspectives.

Plo I, Vainchenker W.

Clin Lymphoma Myeloma. 2009;9 Suppl 3:S329-39. doi: 10.3816/CLM.2009.s.032. Review.

PMID:
19778861
16.

Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms.

Ha JS, Kim YK, Jung SI, Jung HR, Chung IS.

Ann Lab Med. 2012 Nov;32(6):385-91. doi: 10.3343/alm.2012.32.6.385. Epub 2012 Oct 17.

17.

Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.

Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, Gangat N, Fjerza R, Belachew AA, Lasho TL, Ketterling RP, Hanson CA, Rambaldi A, Finazzi G, Thiele J, Barbui T, Pardanani A, Vannucchi AM.

Blood. 2014 Oct 16;124(16):2507-13; quiz 2615. doi: 10.1182/blood-2014-05-579136. Epub 2014 Jul 18.

18.

Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.

Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A.

Leukemia. 2008 Jul;22(7):1299-307. doi: 10.1038/leu.2008.113. Epub 2008 May 22. Review.

PMID:
18496562
19.

Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.

Hahm C, Huh HJ, Mun YC, Seong CM, Chung WS, Huh J.

Int J Lab Hematol. 2015 Apr;37(2):181-9. doi: 10.1111/ijlh.12257. Epub 2014 May 21.

PMID:
24845343
20.

JAK2 and MPL mutations in myeloproliferative neoplasms.

Koppikar P, Levine RL.

Acta Haematol. 2008;119(4):218-25. doi: 10.1159/000140634. Epub 2008 Jun 20. Review.

PMID:
18566540

Supplemental Content

Support Center